Ksawatsالنسخة العربية

Saudi-British Cooperation to Develop Innovative Therapies and Facilitate Patient Access

17 November 2026 ·

Saudi-British Cooperation to Develop Innovative Therapies and Facilitate Patient Access
▪︎ Kingdom WhatsApp .

تعاون سعودي بريطاني لتطوير العلاجات المبتكرة وتيسير وصولها للمرضى

The Saudi Food and Drug Authority signed a memorandum of understanding with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on the sidelines of the DIA-MHRA Global Summit, held in the British capital London on November 16 and 17.

The memorandum aims to develop methods for evaluating innovative therapies and facilitate timely patient access to them, while maintaining safety, quality and efficacy standards. It builds on existing cooperation between the two sides and their shared vision regarding the importance of keeping pace with medical innovation.

Employing artificial intelligence and computational simulation technologies in clinical studies and trials

Areas of cooperation include the evaluation of therapies for rare diseases, advanced therapies and biotechnology products, as well as exchanging expertise in employing artificial intelligence, modeling and computational simulation technologies in clinical studies and trials. This helps clarify regulatory requirements for developers at early stages, particularly when developing treatments for patients with limited therapeutic options.

The memorandum also covers the exchange of information and expertise on the registration and evaluation of medical products, good manufacturing practices and quality systems, and the inspection, analysis and supply chain monitoring of products, thereby supporting the safety of medical products in both countries' markets and enhancing both sides' ability to monitor associated risks.

This cooperation supports the goals of Saudi Vision 2030 in improving quality of life by facilitating patient access to safe and effective therapies. It also aligns with the orientations of the National Biotechnology Strategy in developing national capabilities and supporting innovation in this sector, through the exchange of scientific expertise and the development of regulatory evaluation methods for biologics and advanced therapies.

The memorandum was signed by SFDA CEO Dr. Hisham Aljadhey and MHRA Chief Executive Laurence Tallon, in the presence of the agency's board chairman Professor Anthony Harnden. The two sides held a meeting during which they discussed cooperation priorities in light of scientific and regulatory developments.

● Notice to (new) website visitors:-You can subscribe to the news via WhatsApp for freeClick hereto receive everything new and exclusive.
Source akhbaar24
Originally published in Arabic on Ksawats — 17 November 2026. Read the original in Arabic.